

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA: Erlotinib for the first-line treatment of EGFR-TK mutation positive non-small-cell lung cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Consultees highlighted that drugs such as erlotinib and gefitinib (tyrosine kinase inhibitors) are less toxic than standard chemotherapy and therefore they provide additional treatment options for some patients (such as those who are less fit or elderly) who might have otherwise been denied treatment.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Consultees acknowledged that this is not a specific equality issue. However, the Committee will consider the health needs of all patients included in the population under consideration in the appraisal.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes to the scope required.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes

to the matrix been made?
No

Approved by Associate Director (name): Helen Knight

Date: 01/08/2011